<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286672</url>
  </required_header>
  <id_info>
    <org_study_id>MmBC</org_study_id>
    <nct_id>NCT04286672</nct_id>
  </id_info>
  <brief_title>Metadherin mRNA Expression in Bladder Cancer</brief_title>
  <official_title>Serum Metadherin mRNA Expression in Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to study alterations of MTDH gene expression in the serum of bladder cancer
      patients compared to control group to evaluate its role as a marker for diagnosis.

      ,to compare the diagnostic accuracy of MTDH with the previously used marker Bladder
      Cancer-Specific Antigen-1 (BLCA-1 in the serum of bladder cancer patients .

      and to study correlation between expression of the metadherin gene and serum level of BLCA-1,
      and clinical and histopathological staging in patients with bladder cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urinary bladder cancer (BC) is the ninth most common cancer worldwide. It is the fifth most
      common malignancy in males and seventeenth most common in females.

      In Egypt, bladder cancer represents a massive health burden where it is one of the commonest
      cancers representing 6.9% in both sexes and 10.7% among men. Its distribution is 8.8% in
      lower Egypt, 14.2% in middle Egypt and 12.6% in upper Egypt.Almost 50% of patients will
      experience recurrence of their disease within 4 years of their initial diagnosis.The
      prognosis of bladder cancer is poor as a result of highly invasive properties of tumour
      cells.

      The optimal treatment selection depends on early diagnosis as well as accurate staging and
      grading.Currently there is a need for new molecular bio markers that can help clinicians to
      identify patients requiring early, aggressive treatment.

      Metadherin (MTDH) is an oncogene known as Astrocytic elevated gene-1(AEG-1).It was firstly
      identified in 2002 at fetal astrocytes of persons exposed to HIV-1 and then known as a vital
      oncogene mediating carcinogenesis,prognosis,invasion and cancer metastasis. AEG-1 expression
      is raised in bladder cancer tissues relative to normal tissues, and serves as a poor
      prognostic factor.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>early diagnosis of bladder cancer patient</measure>
    <time_frame>baseline</time_frame>
    <description>study mRNA MTDH expression in the serum of bladder cancer patients compared to control group to evaluate its role as a marker for diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>non invasive marker for detection of bladder cancer.</measure>
    <time_frame>baseline</time_frame>
    <description>To compare the diagnostic accuracy of MTDH with the previously used marker Bladder Cancer-Specific Antigen-1 (BLCA-1 in the serum of bladder cancer patients .</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1:</arm_group_label>
    <description>• 35 bladder cancer patients diagnosed by biopsy before treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2:</arm_group_label>
    <description>35 apparently healthy individuals who were matched by age and sex .</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Metadherin</intervention_name>
    <description>study alterations of MTDH gene expression in the serum of bladder cancer patients</description>
    <arm_group_label>Group 1:</arm_group_label>
    <arm_group_label>Group 2:</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Group 1: 35 bladder cancer patients diagnosed by biopsy before treatment.

          -  Group 2: 35 apparently healthy individuals who were matched by age and sex .
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females.

          -  30-80 years old.

          -  patients with bladder cancer not receiving any treatment

        Exclusion Criteria:

          1. patients taking chemotherapy or radiotherapy.

          2. History of other malignancy.

          3. History of autoimmune diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lubna M. Tag El-Din, Doctorate</last_name>
    <role>Study Chair</role>
    <affiliation>Lubna Mohamed Tag El-Din</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esraa N. Abd-el-Hakim, Master</last_name>
    <phone>01007246740</phone>
    <email>esraanasr1991@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amal M. Abdel -Aal, Doctorate</last_name>
    <phone>01225433428</phone>
    <email>amalabdelaaal95@gmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Abdel-Rahman O, Helbling D, Schöb O, Eltobgy M, Mohamed H, Schmidt J, Giryes A, Mehrabi A, Iype S, John H, Tekbas A, Zidan A, Oweira H. Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: An updated systematic review of 81 epidemiological studies. J Evid Based Med. 2017 Nov;10(4):245-254. doi: 10.1111/jebm.12270. Epub 2017 Sep 10. Review.</citation>
    <PMID>28891275</PMID>
  </results_reference>
  <results_reference>
    <citation>Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013 Feb;63(2):234-41. doi: 10.1016/j.eururo.2012.07.033. Epub 2012 Jul 25. Review.</citation>
    <PMID>22877502</PMID>
  </results_reference>
  <results_reference>
    <citation>Giopanou I, Bravou V, Papanastasopoulos P, Lilis I, Aroukatos P, Papachristou D, Kounelis S, Papadaki H. Metadherin, p50, and p65 expression in epithelial ovarian neoplasms: an immunohistochemical study. Biomed Res Int. 2014;2014:178410. doi: 10.1155/2014/178410. Epub 2014 May 22.</citation>
    <PMID>24963474</PMID>
  </results_reference>
  <results_reference>
    <citation>Guszcz T, Szymańska B, Kozlowski R, Lukaszewski Z, Laskowski P, Gorodkiewicz E. Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis. Oncol Lett. 2020 Jan;19(1):562-568. doi: 10.3892/ol.2019.11080. Epub 2019 Nov 11.</citation>
    <PMID>31897172</PMID>
  </results_reference>
  <results_reference>
    <citation>Hu B, Emdad L, Kegelman TP, Shen XN, Das SK, Sarkar D, Fisher PB. Astrocyte Elevated Gene-1 Regulates β-Catenin Signaling to Maintain Glioma Stem-like Stemness and Self-Renewal. Mol Cancer Res. 2017 Feb;15(2):225-233. doi: 10.1158/1541-7786.MCR-16-0239. Epub 2016 Nov 30.</citation>
    <PMID>27903708</PMID>
  </results_reference>
  <results_reference>
    <citation>Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ, Fisher PB. Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene. 2005 Jun 20;353(1):8-15.</citation>
    <PMID>15927426</PMID>
  </results_reference>
  <results_reference>
    <citation>Li G, Wang Z, Ye J, Zhang X, Wu H, Peng J, Song W, Chen C, Cai S, He Y, Xu J. Uncontrolled inflammation induced by AEG-1 promotes gastric cancer and poor prognosis. Cancer Res. 2014 Oct 1;74(19):5541-52. doi: 10.1158/0008-5472.CAN-14-0968. Epub 2014 Aug 4.</citation>
    <PMID>25092897</PMID>
  </results_reference>
  <results_reference>
    <citation>Pan Y, Guo X, Yang Z, Chen S, Lei Y, Lin M, Wang L, Feng C, Ke Z. AEG-1 activates Wnt/PCP signaling to promote metastasis in tongue squamous cell carcinoma. Oncotarget. 2016 Jan 12;7(2):2093-104. doi: 10.18632/oncotarget.6573.</citation>
    <PMID>26689985</PMID>
  </results_reference>
  <results_reference>
    <citation>Park SY, Choi M, Park D, Jeong M, Ahn KS, Lee J, Fisher PB, Yun M, Lee SG. AEG-1 promotes mesenchymal transition through the activation of Rho GTPases in human glioblastoma cells. Oncol Rep. 2016 Nov;36(5):2641-2646. doi: 10.3892/or.2016.5106. Epub 2016 Sep 19.</citation>
    <PMID>27667169</PMID>
  </results_reference>
  <results_reference>
    <citation>Sarkar D, Park ES, Emdad L, Lee SG, Su ZZ, Fisher PB. Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1. Cancer Res. 2008 Mar 1;68(5):1478-84. doi: 10.1158/0008-5472.CAN-07-6164.</citation>
    <PMID>18316612</PMID>
  </results_reference>
  <results_reference>
    <citation>Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao W, Volsky DJ, Fisher PB. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene. 2002 May 16;21(22):3592-602.</citation>
    <PMID>12032861</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang L, Yang G, Chen H, Huang Y, Xue W, Bo J. Depletion of astrocyte elevated gene-1 suppresses tumorigenesis through inhibition of Akt activity in bladder cancer cells. Am J Transl Res. 2017 Dec 15;9(12):5422-5431. eCollection 2017.</citation>
    <PMID>29312494</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Esraa Nasr Abd-el-hakim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

